MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States

October 25, 2011

MILAN, ITALY-- - MolMed S.p.A. announces the expansion in the United States of a pivotal Phase III trial of its investigational anticancer drug NGR-hTNF in malignant pleural mesothelioma, with treatment ...


Read the full story: MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States

Mesothelioma Doctors Mesothelioma Support Groups Mesothelioma Clinical Trials